Grey Wolf Receives additional $50M in Series B Financing

In order to further develop its antigen modulation technology, Grey Wolf Therapeutics has completed a $50 million Series B fundraising extension.

The Series B extension was led by ICG, with backing from Pfizer Ventures, Canaan, Andera Partners among other current investors.

With this transaction, the Series B equity total jumped to $99 million.

The money will make it easier to extend the business’s antigen modulation technology studies and development activities into prospective autoimmune disease therapies.